LCID
Lucid Group, Inc.
LCID offers stronger valuation, but that advantage does not outweigh its weaker overall profile.
MRVL
Marvell Technology, Inc.
MRVL has the edge over LCID overall, supported by stronger fundamentals and stronger modeled upside.
LCID Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Weak | |
| Weak | |
| Unavailable |
LCID's revenue is currently healthy, but its profitability and cash flow are weak. There isn't enough data to rate its balance sheet.
MRVL Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Healthy |
MRVL's revenue, profitability, cash flow and balance sheet are all currently healthy.
LCID PE Valuation
LCID has no meaningful PE right now: it lost money over the past year.
MRVL PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 17x | $51.02 | -69% |
| Fair | 25x | $75.19 | -54% |
| Forward | 25x | $164 | — |
| Current | 54x | $164 | — |
| Expensive | 71x | $215 | +31% |
Historical ranges are pointers, not guarantees.
MRVL's PE is in its expensive range at 54x. If earnings grow as analysts expect, today's price would be 25x next year's earnings, in its fair range.
LCID Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| -- | |
| Limited | |
| Low |
Analysts expect LCID's losses to shrink, with revenue growing. However, they disagree widely on these estimates.
MRVL Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Moderate | |
| Moderate |
Analysts expect strong earnings and revenue growth for MRVL, with profitability improving.
LCID Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$13.08 | -$2.57 |
| Q2 2026 | -$13.65 | -$2.35 |
| Q1 2026 | -$13.15 | -$1.25 |
| Q4 2025 | -$12.09 | +$0.41 |
| Q3 2025 | -$10.51 | +$2.49 |
| Q2 2025 | -$11.30 | +$0.40 |
| Q1 2025 | -$11.90 | +$0.40 |
| Q4 2024 | -$12.50 | +$1.10 |
LCID is still losing money, but less than at its worst: $13.08 per share over the past year, against $16.50 at its worst in mid-2023.
MRVL Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $6.51 | +116% |
| Q3 2026 | $3.02 | +$3.15 |
| Q2 2026 | $2.91 | +$3.48 |
| Q1 2026 | $3.07 | +$4.09 |
| Q4 2025 | $2.85 | +$4.55 |
| Q3 2025 | -$0.13 | +$0.98 |
| Q2 2025 | -$0.57 | +$0.56 |
| Q1 2025 | -$1.02 | +$0.06 |
| Q4 2024 | -$1.70 | -$1.05 |
MRVL has the edge over LCID on earnings quality, reporting a profit while its opponent remains loss making.
LCID Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $350.3M | +4.1% |
| Q2 2026 | $405.3M | +56% |
| Q1 2026 | $282.5M | +20% |
| Q4 2025 | $522.7M | +123% |
| Q3 2025 | $336.6M | +68% |
| Q2 2025 | $259.4M | +29% |
| Q1 2025 | $235M | +36% |
| Q4 2024 | $234.5M | +49% |
LCID has the edge over MRVL on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -245% | +35 points |
| Q2 2026 | -267% | +43 points |
| Q1 2026 | -350% | -56 points |
| Q4 2025 | -204% | +109 points |
| Q3 2025 | -280% | +105 points |
| Q2 2025 | -310% | +83 points |
| Q1 2025 | -294% | +128 points |
| Q4 2024 | -313% | +156 points |
LCID's operating margin was −245% last quarter, up 35 points from the same quarter a year ago, near the top of its range since 2020.
MRVL Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $2.7B | +37% |
| Q2 2026 | $2.4B | +28% |
| Q1 2026 | $2.2B | +22% |
| Q4 2025 | $2.1B | +37% |
| Q3 2025 | $2B | +58% |
| Q2 2025 | $1.9B | +63% |
| Q1 2025 | $1.8B | +27% |
| Q4 2024 | $1.5B | +6.9% |
MRVL's revenue has grown year over year for eight quarters in a row: $2.7B last quarter, up 37% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 17% | +2.3 points |
| Q2 2026 | 14% | -0.2 points |
| Q1 2026 | 18% | +5.3 points |
| Q4 2025 | 17% | +64 points |
| Q3 2025 | 14% | +22 points |
| Q2 2025 | 14% | +27 points |
| Q1 2025 | 13% | +15 points |
| Q4 2024 | -46% | -36 points |
MRVL has the edge over LCID on profitability, with a higher operating margin.
LCID Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1B | -$84.2M |
| Q2 2026 | -$1.5B | -$463.2M |
| Q1 2026 | -$1.4B | -$849M |
| Q4 2025 | -$1.2B | -$417.1M |
| Q3 2025 | -$955.5M | -$333M |
| Q2 2025 | -$1B | -$271.6M |
| Q1 2025 | -$589.9M | +$125.1M |
| Q4 2024 | -$824.8M | -$77.6M |
LCID has burned cash in almost every quarter: −$5.2B over the past year, against −$3.4B the year before.
MRVL Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $478.8M | +16% |
| Q2 2026 | $483.1M | +126% |
| Q1 2026 | $259.4M | -42% |
| Q4 2025 | $508.8M | +10% |
| Q3 2025 | $414.1M | +60% |
| Q2 2025 | $214.1M | -8.1% |
| Q1 2025 | $444.1M | -6.6% |
| Q4 2024 | $461.3M | +2.8% |
MRVL has the edge over LCID on cash generation, producing positive trailing cash flow while its opponent burns cash.
LCID Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.3% | +12.5M shares |
| 1 year | +26% | +82.4M shares |
| 3 years | +73% | +166M shares |
LCID has 395M diluted shares, up 26% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | $2.2M |
| Q1 2020 | — |
MRVL Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.1% | +27.9M shares |
| 1 year | +5.8% | +50.8M shares |
| 3 years | +7% | +60.3M shares |
| 5 years | +12% | +100M shares |
| Available history | +38% | +253M shares |
MRVL has the edge over LCID on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $200M |
| Q2 2026 | $200M |
| Q1 2026 | $200.1M |
| Q4 2025 | $1.3B |
| Q3 2025 | $200M |
| Q2 2025 | $340M |
| Q1 2025 | $200M |
| Q4 2024 | $200M |
MRVL spent $1.9B buying back its own shares over the past year, up 102% from the year before.
LCID Net Leverage
LCID's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
MRVL Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2021 | 1.5x | Healthy |
| Q4 2020 | 0.5x | Very low |
| Q3 2020 | 0.6x | Very low |
| Q2 2020 | 0.7x | Very low |
| Q1 2020 | 0.7x | Very low |
| Q4 2019 | 5.3x | High |
MRVL's net debt is about 1.5 years of its operating earnings (EBITDA), up from less than a year a year ago.
LCID Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 32.9 | Neutral |
| Stochastic | 7.1 | Oversold |
LCID's weekly RSI is 33 (neutral) and its Stochastic is 7 (oversold).
MRVL Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 41.9 | Neutral |
| Stochastic | 16.1 | Oversold |
MRVL's weekly RSI is 42 (neutral) and its Stochastic is 16 (oversold).
LCID PE vs Consumer Cyclical Sector
LCID has no meaningful PE right now: it lost money over the past year.
MRVL PE vs Technology Sector
| Metric | MRVL | Sector median | Relative |
|---|---|---|---|
| PE | 54x | 28x | 95% above |
| PE % | 75 | 35 | 40 pts above |
MRVL is trading at 54x earnings, a 95% premium to the Technology sector's median of 28x.
LCID Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $3.53 | 7.9% below |
| 20 week MA | $4.88 | 33% below |
| 50 week MA | $7.33 | 56% below |
| 100 week MA | $15.4 | 79% below |
| 200 week MA | $31.9 | 90% below |
LCID is in a downtrend: it's below all five of its weekly moving averages, and 90% below its 200-week average.
MRVL Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $221.0 | 26% below |
| 20 week MA | $220.9 | 26% below |
| 50 week MA | $168.8 | 2.5% below |
| 100 week MA | $124.8 | 32% above |
| 200 week MA | $93.8 | 75% above |
MRVL has the edge over LCID on trend strength, trading above more of its moving averages.
LCID Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $98.9 | $100.4 | +1.5% |
| 2021 | $100.4 | $376.4 | +275% |
| 2022 | $376.4 | $67.0 | -82% |
| 2023 | $67.0 | $42.1 | -37% |
| 2024 | $42.1 | $32.0 | -24% |
| 2025 | $32.0 | $11.4 | -64% |
| 2026 YTD | $11.4 | $3.25 | -72% |
LCID has finished four years in a row lower, and it's down 72% so far in 2026.
MRVL Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $26.7 | $47.1 | +76% |
| 2021 | $47.1 | $87.7 | +86% |
| 2022 | $87.7 | $37.2 | -58% |
| 2023 | $37.2 | $60.3 | +62% |
| 2024 | $60.3 | $113.6 | +88% |
| 2025 | $113.6 | $86.3 | -24% |
| 2026 YTD | $86.3 | $164.5 | +90% |
MRVL has the edge over LCID on returns for 2026, with the stronger performance.